IRON: Promising late-stage data and strong market potential position both programs for significant impact
DISC-3405 shows promising efficacy and safety in PV, with plans for phase III and potential as a frontline therapy. Bitopertin's APOLLO phase III trial is well-powered, targeting a rare disease with significant unmet need, and top-line data are expected in Q4. Both programs address large, underappr…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.